Guselkumab Phase 3 Psoriasis Trial in Skin of Color Completes Primary Data

The Phase 3 study (NCT05272150) investigating guselkumab for moderate-to-severe plaque and/or scalp psoriasis in skin of color participants completed its primary data collection on 2025-05-30. This trial enrolled 213 participants to evaluate the drug's efficacy against placebo.

Background

Guselkumab, marketed as Tremfya, is a biologic medication approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. It is an interleukin-23 (IL-23) inhibitor, which works by targeting a specific protein involved in the inflammatory process of psoriasis. This particular Phase 3 study focused on individuals with skin of color, a population often underrepresented in clinical trials, to specifically evaluate the drug's effectiveness in treating moderate-to-severe plaque and/or scalp psoriasis within this demographic.

Trial design

The study (NCT05272150) is a Phase 3 trial designed to evaluate the efficacy of guselkumab treatment versus placebo. It enrolled 213 participants diagnosed with moderate-to-severe plaque and/or scalp psoriasis, specifically focusing on individuals with skin of color. The trial's purpose was to assess improvements in the signs and symptoms of psoriasis in this specific population.

What this means

The primary completion of this Phase 3 trial for guselkumab marks a significant step towards understanding its efficacy and safety in a specific and important patient population. Clinical trials that specifically include participants with skin of color are vital for addressing health disparities and ensuring that treatment options are well-characterized across diverse ethnic and racial groups. The eventual data from this trial will be crucial for clinicians to make informed decisions for their patients with moderate-to-severe plaque and/or scalp psoriasis, particularly those with skin of color, by providing evidence tailored to their specific needs and responses.

Source

Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05272150, titled "Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis," was noted on 2025-05-30 on clinicaltrials.gov.